





Suppl. Figure 1: A) Western blot analysis of bulk KPC tumours (n=6), cancer associated fibroblast cell lines (CAFs, n=4) and KPC tumour cell lines (n=2) reveals predominant expression of SPARC in CAFs.




Suppl. Figure 2: A+B) C57B6 mice were treated with a single dose of *nab*-paclitaxel (n=5) or *m-nab*paclitaxel (n=5) at 30mg/kg by i.v. injection. Plasma and kidney tissues were harvested and assessed for paclitaxel levels 2h later by LC-MS/MS. **C)** Schematic of long-term trial for 60mg/kg *m-nab*-paclitaxel in tumour-bearing KPC mice (n=8).







Suppl. Figure 3: A) Western blot analysis of whole tissue lysates from SPARC^{-/-} (n=2) and SPARC^{+/+} mice (n=2) from pancreas, kidney, liver and testis showing a faint expression of SPARC in normal pancreas and liver, and no detectable SPARC expression in SPARC^{+/+} kidney samples. **B)** SPARC plasma levels in SPARC^{-/-} mice (n=4), SPARC^{+/+} mice (n=7) and tumour-bearing KPC mice (n=7, *p<0.05 compared to SPARC^{-/-}) by enzyme-linked immunosorbent assay. **C)** Mean vessel density (CD31) immunohistochemistry shows no significant differences between KPfC SPARC^{+/+} and KPfC SPARC^{-/-} testis tissue.



Suppl. Figure 4: **A)** Automated quantification of 30 randomly chosen fields for proliferation (ki67) and **B)** mean vessel density (CD31) immunohistochemistry shows no significant differences between KPfC SPARC^{+/+} and KPfC SPARC^{-/-} mice.



Suppl. Figure 5: LC-MS/MS analysis from **A)** kidney and **B)** plasma samples harvested from KPfC SPARC^{+/+} and KPfC SPARC^{-/-} mice 2h post intravenous injection of 60mg/kg *m-nabpaclitaxel*. **C)** Pre-enrolment tumour volumes of the 7d short term study (KPfC SPARC^{+/+}, n=6; and KPfC SPARC^{-/-}, n=5) showing no significant differences prior to enrolment. **D)** Schematic of short-term trial for 60mg/kg *m-nab-paclitaxel* in tumourbearing KPfC SPARC^{+/+} and KPfC SPARC^{-/-} mice. **E)** Analysis of terminal blood draws reveals no relevant differences in white blood cell count (WBC), neutrophil/granulocyte count, platelet count, and haemoglobin (Hb) in KPfC SPARC^{+/+} and KPfC SPARC^{-/-}.



E

Parameter	KPC <i>SPARC</i> null (n=5)	KPC <i>SPARC</i> wildtype (n=6)
Hb (g/dl)	10.7 ± 1.76	9.0 ± 2.36
WBC (10 ⁶ cell/ml)	6.95 ± 3.42	3.16 ± 1.45
Neutrophils (10 ⁶ cell/ml)	1.52 ± 0.66	0.933 ± 1.17
Platelets (10 ⁶ cell/ml)	811.3 ± 395.2	1014 ± 149.1